CRISPR/Cas13-mediated Dynamin 2 reduction therapy in a canine model of <i>DNM2</i> -related centronuclear myopathy

bioRxiv (Cold Spring Harbor Laboratory)
September 5, 2025
Cited by 0


Related Papers